CN110283728A - The tetralone derivative and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source - Google Patents
The tetralone derivative and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source Download PDFInfo
- Publication number
- CN110283728A CN110283728A CN201910427992.9A CN201910427992A CN110283728A CN 110283728 A CN110283728 A CN 110283728A CN 201910427992 A CN201910427992 A CN 201910427992A CN 110283728 A CN110283728 A CN 110283728A
- Authority
- CN
- China
- Prior art keywords
- cusp
- mangrove
- endogenetic fungus
- tetralone derivative
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/747—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
- C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
- C12P7/26—Ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to the tetralone derivative and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source, the tetralone derivative has structure shown in compound 1-5:
Description
Technical field
The invention belongs to mangrove endogenetic fungus secondary metabolite fields, and in particular to mangrove cusp sea lotus endogenetic fungus comes
The tetralone derivative in source and the preparation method and application thereof.
Background technique
One of unique compound important sources of endogenetic fungus structure novel activity of marine source, applicant is previously from red
It sets separation in cusp sea lotus endogenetic fungus TGM112 and obtains the active mixed first terpenoid of series pesticide.The present invention is from another strain
Separation obtains serial tetralone derivative in mangrove cusp sea lotus endogenetic fungus (CGMCC No.17674).
Summary of the invention
The present invention provides a kind of mangrove cusp sea lotus endogenetic fungus, it is characterised in that its culture presevation information: depositary institution
Title: China Committee for Culture Collection of Microorganisms's common micro-organisms center；Depositary institution address: the Chaoyang District, Beijing City North Star
The institute 3 of West Road 1, Institute of Microorganism, Academia Sinica；Preservation date: on April 24th, 2019；Deposit number: CGMCC
No.17674；Classification naming: Daldinia eschscholtzii.
Another embodiment of the present invention provides the tetralone derivative in above-mentioned mangrove cusp sea lotus endogenetic fungus source
Or its pharmaceutically acceptable salt, it is characterised in that the tetralone derivative has structure shown in compound 1-5:
Another embodiment of the present invention provides above-mentioned mangrove cusp sea lotus endogenetic fungus and spreads out preparing above-mentioned tetralone
Application in biology.
Another implementation of the invention provide it is a kind of using above-mentioned mangrove cusp sea lotus endogenetic fungus simultaneously prepare compound 1-5
Preparation method, it is characterised in that include the following steps:
(1) prepare seed culture medium, by above-mentioned mangrove cusp sea lotus endogenetic fungus access seed culture medium, 26~28 DEG C,
Obtain seed culture fluid within culture 3~4 days；
(2) in the seed culture fluid access fermentation medium obtained step (1), 26~28 DEG C stationary culture 21~24 days
Obtain fermentation material；
(3) fermentation liquid in the fermentation material for obtaining step (2) and thallus separation, the isometric ethyl acetate of fermentation liquid
Extraction 3~5 times, is concentrated under reduced pressure to give medicinal extract after combining extraction liquid；Compound 1-5 is obtained through chromatographic isolation.
Contain glucose 1.5% -3.0%, yeast extract 0.1% -0.5%, peptone in step (1) described seed culture medium
0.1% -0.5%, coarse sea salt 0.11% -0.6%, suitable water；Contain glucose in step (2) described fermentation medium
1.6% -3.5%, yeast extract 0.1% -0.5%, peptone 0.1% -0.5%, coarse sea salt 0.11% -0.6%, suitable water；
Above-mentioned percentage is weight percentage；The seed culture medium and fermentation medium are both needed to 120 DEG C and go out 25-30 minutes；Step
(3) the preferred normal-phase silica gel column chromatography of the chromatographic isolation, reversed silica gel column chromatography, LH-20 gel filtration chromatography, efficient liquid phase HPLC
One or more of preparation combines.
Another embodiment of the present invention provides above-mentioned tetralone derivative or prepared by its pharmaceutically acceptable salt
Application in prevention and/or treatment diabetes medicament.
Another embodiment of the present invention provides above-mentioned tetralone derivative or prepared by its pharmaceutically acceptable salt
Application in alpha-glucosidase restrainer.
A kind of pharmaceutical composition, it is characterised in that the pharmaceutical composition with above-mentioned tetralone derivative or its pharmaceutically may be used
The salt of receiving is as effective component.The pharmaceutical composition may also include other preventions and/or treatment diabetes medicament.The medicine group
Closing object may also include the auxiliary material that can pharmaceutically connect.The preferred solid pharmaceutical preparation of the dosage form of the pharmaceutical composition or liquid preparation etc..
Term " pharmaceutically acceptable salt " refers to the addition of atoxic inorganic or organic acid and/or alkali in the present invention
Salt, reference can be made to " Salt selection for basic drugs ", Int.J.Pharm. (1986), 33,201-217.
It should be understood that within the scope of the present invention, above-mentioned each technical characteristic of the invention and in below (eg embodiment) specifically
Each technical characteristic of description can be combined with each other, to form a new or preferred technical solution.As space is limited, not another herein
One tired states.
Detailed description of the invention
Fig. 1 is compound 1-51H-1H COSY figure related to HMBC；
Fig. 2 is the ECD spectrogram of compound 1 and 2；
Fig. 3 is the ECD figure of compound 3；
Fig. 4 is the ECD spectrogram of compound 4；
Fig. 5 is the colony characteristics figure of mangrove cusp of the present invention sea lotus endogenetic fungus (CGMCC No.17674).
Specific embodiment
For the ease of a further understanding of the present invention, examples provided below has done more detailed description to it.But
It is that these embodiments are only not supposed to be a limitation to the present invention or implementation principle for better understanding invention, reality of the invention
The mode of applying is not limited to the following contents.
Embodiment 1
(1) Spawn incubation
Prepare seed culture medium: glucose 80g, peptone 8g, yeast extract 8g, coarse sea salt 10g, water 4.0L, average packing
In 8 1000mL conical flasks, 120 DEG C go out 25-30 minutes.
Mangrove cusp sea lotus endogenetic fungus (CGMCC No.17674) is accessed in prepared seed culture medium, in 26~
At 28 DEG C, seed culture fluid is obtained within culture 3 days；
(2) it ferments
Preparation fermentation medium: glucose 1.1kg, peptone 100g, yeast extract 100g, sea salt 125g, water 50L are average
It is sub-packed in 75 1000mL conical flasks, 120 DEG C go out 25-30 minutes.
The access of seed culture fluid obtained in appropriate step (1) is taken equipped in the conical flask of fermentation medium, in 26~
28 DEG C obtain fermentation material in stationary culture 21 days.
(3) it isolates and purifies
Fermentation liquid in fermentation material and the thallus separation that step (2) is obtained, the isometric ethyl acetate extraction of fermentation liquid
It takes 3 times, medicinal extract is concentrated under reduced pressure to give after combining extraction liquid；Decompression silica gel column chromatography is first passed through, is pressed using petroleum ether-ethyl acetate
100:0,90:10,80:20,70:30,60:40,50:50,40:60,30:70,20:80,10:90,0:100 gradient elution, often
A gradient collects two column volumes, through reversed silica gel column chromatography, eluant, eluent after the fraction concentration that wherein 30:70 gradient elution obtains
For methanol: water=1:1-1:0, then prepared through high-efficient liquid phase chromatogram HPLC, chromatographic column is the μ of Agilent C18,9.4 × 250mm, 7
M, flow velocity 2mL/min, mobile phase MeOH:H2O=55:45 finally obtains compound 2 (3.5mg), 3 (6.3mg), 4
(8.1mg)；Through Sephadex LH-20 gel filtration chromatography after the fraction concentration that wherein 40:60 gradient obtains, eluant, eluent is chloroform:
Methanol=1:1 obtains compound 1 (7.3mg) and 5 (10.4mg)；The ratio of the eluant, eluent or mobile phase is volume ratio.Change
The structural identification data for closing object 1-5 is as follows:
Compound 1:[α]25 D-14.4(c 0.12,MeOH)；UV(MeOH)λmax(logε)221,254,300nm；IR
(KBr)νmax 3400,3263,2974,1685,1612cm-1；CD(c 0.3,MeOH)λmax(Δε)204(+10.57),259(-
9.63),304(+3.60)nm；1H and 13C NMR is shown in Table 1-2；HR-ESI-MS m/z:223.0964[M+H]+,(C12H15O4,
calcd for 223.0965).
Compound 2:[α]25 D-14.0(c 0.20,MeOH)；UV(MeOH)λmax(logε)221,254,300nm；IR
(KBr)νmax 3400,3263,2974,1685,1612,1495cm-1；CD(c 0.4,MeOH)λmax(Δε)204(+14.9),
261(-12.5),304(+6.9)nm；1H and 13C NMR is shown in Table 1-2；HR-ESI-MS m/z:251.1273[M+H]+,
(C14H19O4,calcd for 251.1278).
Compound 3:[α]25 D+35.6(c 0.15,MeOH)；IR(KBr)νmax 3490,3400,2930,1670,1565,
1490cm-1；CD(c 0.52,MeOH)λmax(Δε)212(-28.98),236(+3.16),286(+11.60),344(-0.33)
nm；1H and 13C NMR is shown in Table 1-2；HR-ESI-MS m/z:265.1434[M+H]+,(C15H21O4,calcd for
265.1434).
Compound 4:[α]25 D-41.9(c 0.18,MeOH)；IR(KBr)νmax 3490,3400,2930,1670,1565,
1490cm-1；CD(c 0.60,MeOH)λmax(Δε)212(-45.27),236(+8.21),286(+32.9),313(-21.86)
nm；1H and 13C NMR is shown in Table 1-2；HR-ESI-MS m/z:265.1434[M+H]+,(C15H21O4,calcd for
265.1434).
Compound 5:UV (MeOH) λmax(logε)221,254,300nm；IR(KBr)νmax 3250,2974,1685,
1612,1595cm-1；1H and 13C NMR is shown in Table 3；HR-ESI-MS m/z:277.1078[M+H]+,(C15H17O5,calcd
for 277.1071).
1. compound 1-4's of table1H NMR(400MHz,CDCl3)
2. compound 1-4's of table13C NMR(100MHz,CDCl3)
3. compound 5 of table1H (400MHz) and13C NMR(100MHz)DMSO-d6
Embodiment 2
According to Chinese invention patent application number: the method test the compounds of this invention 1-5 recorded in 201510880543.1
The IC that alpha-glucosidase is inhibited50, using Acarbose as positive control, as a result see the table below.
The IC of compound 150> 50, active testing is the result shows that 7 ethyls replace to alpha-glucosidase inhibition work in structure
Property is advantageous.
Claims (10)
1. a kind of mangrove cusp sea lotus endogenetic fungus, it is characterised in that its culture presevation information: depositary institution's title: the micro- life of China
Object culture presevation administration committee common micro-organisms center；Depositary institution address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3,
Institute of Microorganism, Academia Sinica；Preservation date: on April 24th, 2019；Deposit number: CGMCC No.17674；Classification life
Name: Daldinia eschscholtzii.
2. the tetralone derivative or its pharmaceutically acceptable salt in mangrove cusp sea lotus endogenetic fungus source, it is characterised in that
The tetralone derivative has structure shown in compound 1-5:
3. mangrove cusp described in claim 1 sea lotus endogenetic fungus is preparing tetralone derivative as claimed in claim 2
In application.
4. a kind of prepare chemical combination as claimed in claim 2 using mangrove cusp sea lotus endogenetic fungus described in claim 1 simultaneously
The preparation method of object 1-5, it is characterised in that include the following steps:
(1) seed culture medium is prepared, above-mentioned mangrove cusp sea lotus endogenetic fungus is accessed into seed culture medium, 26~28 DEG C, cultivates 3
Obtain seed culture fluid within~4 days；
(2) in the seed culture fluid access fermentation medium obtained step (1), 26~28 DEG C must send out for stationary culture 21~24 days
Ferment object；
(3) fermentation liquid in the fermentation material for obtaining step (2) and thallus separation, fermentation liquid are extracted with isometric ethyl acetate
3~5 times, medicinal extract is concentrated under reduced pressure to give after combining extraction liquid；Compound 1-5 is obtained through chromatographic isolation.
5. tetralone derivative as claimed in claim 2 or its pharmaceutically acceptable salt are in preparation prevention and/or treatment sugar
Urinate the application in medicine.
6. tetralone derivative as claimed in claim 2 or its pharmaceutically acceptable salt are preparing alpha-glucosidase inhibition
Application in agent.
7. a kind of pharmaceutical composition, it is characterised in that the pharmaceutical composition with tetralone derivative as claimed in claim 2 or
Its pharmaceutically acceptable salt is as effective component.
8. pharmaceutical composition as claimed in claim 7, it is characterised in that the pharmaceutical composition may also include other preventions and/or control
Treat diabetes medicament.
9. the described in any item pharmaceutical compositions of claim 7-8, it is characterised in that the pharmaceutical composition may also include pharmaceutically
The auxiliary material that can be connect.
10. the described in any item pharmaceutical compositions of claim 7-9, it is characterised in that the preferred solid of the dosage form of the pharmaceutical composition
Preparation or liquid preparation etc..
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910427992.9A CN110283728B (en) | 2019-05-22 | 2019-05-22 | Tetralone derivative derived from rosette valve and lotus endophytic fungi as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910427992.9A CN110283728B (en) | 2019-05-22 | 2019-05-22 | Tetralone derivative derived from rosette valve and lotus endophytic fungi as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110283728A true CN110283728A (en) | 2019-09-27 |
| CN110283728B CN110283728B (en) | 2020-09-29 |
Family
ID=68002285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910427992.9A Active CN110283728B (en) | 2019-05-22 | 2019-05-22 | Tetralone derivative derived from rosette valve and lotus endophytic fungi as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110283728B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110257255A (en) * | 2019-05-22 | 2019-09-20 | 海南师范大学 | The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source |
| CN115490661A (en) * | 2022-08-09 | 2022-12-20 | 海南师范大学 | Antioxidant active compound in mangrove-derived fungi and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108640897A (en) * | 2018-04-27 | 2018-10-12 | 海南师范大学 | Polyketides and the preparation method and application thereof in a kind of mangrove endogenetic fungus |
| CN109486685A (en) * | 2018-12-04 | 2019-03-19 | 海南师范大学 | A kind of mangrove cusp sea lotus endogenetic fungus and its application in preparation anti-insect activity terpene crystalline compounds |
| CN109553600A (en) * | 2018-12-04 | 2019-04-02 | 海南师范大学 | Isocoumarin class compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus |
| CN110257255A (en) * | 2019-05-22 | 2019-09-20 | 海南师范大学 | The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source |
-
2019
- 2019-05-22 CN CN201910427992.9A patent/CN110283728B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108640897A (en) * | 2018-04-27 | 2018-10-12 | 海南师范大学 | Polyketides and the preparation method and application thereof in a kind of mangrove endogenetic fungus |
| CN109486685A (en) * | 2018-12-04 | 2019-03-19 | 海南师范大学 | A kind of mangrove cusp sea lotus endogenetic fungus and its application in preparation anti-insect activity terpene crystalline compounds |
| CN109553600A (en) * | 2018-12-04 | 2019-04-02 | 海南师范大学 | Isocoumarin class compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus |
| CN110257255A (en) * | 2019-05-22 | 2019-09-20 | 海南师范大学 | The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source |
Non-Patent Citations (1)
| Title |
|---|
| LU-JIA YANG等: "One new cytochalasin metabolite isolated from a mangrove-derived fungus Daldinia eschscholtzii HJ001", 《NATURAL PRODUCT RESEARCH》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110257255A (en) * | 2019-05-22 | 2019-09-20 | 海南师范大学 | The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source |
| CN110257255B (en) * | 2019-05-22 | 2020-09-29 | 海南师范大学 | Benzopyrone derivative derived from endophytic fungi of mangrove cuspidate and lotus as well as preparation method and application thereof |
| CN115490661A (en) * | 2022-08-09 | 2022-12-20 | 海南师范大学 | Antioxidant active compound in mangrove-derived fungi and preparation method thereof |
| CN115490661B (en) * | 2022-08-09 | 2023-09-08 | 海南师范大学 | Antioxidant active compound in mangrove-derived fungi and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110283728B (en) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110257255A (en) | The chromone derivatives and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source | |
| CN107827805A (en) | A kind of indoles diterpene-kind compound of mangrove xylocarpus granatum originated from fungus and preparation method and application | |
| CN107298672B (en) | Application of seclenic acid I derived from penicillium oxalicum in preparation of anti-human colon cancer drugs | |
| CN110283728A (en) | The tetralone derivative and the preparation method and application thereof in mangrove cusp sea lotus endogenetic fungus source | |
| CN110527629A (en) | A kind of brefeldin A in marine fungi source, preparation method and its application in terms of anti-agriculture pathogenic bacteria | |
| CN109553600A (en) | Isocoumarin class compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus | |
| CN110229127A (en) | A kind of butyrolactone compound and the preparation method and application thereof in mangrove endogenetic fungus source | |
| CN109486685A (en) | A kind of mangrove cusp sea lotus endogenetic fungus and its application in preparation anti-insect activity terpene crystalline compounds | |
| CN107828663A (en) | A kind of indoles diterpene-kind compound crystal and its application as antineoplastic | |
| CN113801032A (en) | Long-chain fatty acid glycerol alcohol compound Rubracin B, preparation method and application thereof | |
| CN108640897A (en) | Polyketides and the preparation method and application thereof in a kind of mangrove endogenetic fungus | |
| CN108586380A (en) | A kind of natural Rakicidins classes compound R akicidin H and its extracting method | |
| CN110627760B (en) | Compound (+/-) -Lucidumone, preparation method thereof and application thereof in pharmacy and food | |
| CN109824689A (en) | Meroterpenoids compound and the preparation method and application thereof in a kind of mangrove endogenetic fungus | |
| CN103910701A (en) | Marine fungus-derived naphthoquinone compound, and preparation method and application thereof | |
| CN108558606B (en) | Sesterterpene compound peniroquesines, and preparation method and application thereof | |
| CN109810919A (en) | A kind of An Shaquan carbocyclic ring polyketide and its application in preparation antibacterials or anti-tumor drug | |
| CN114621092A (en) | Phenolic compound in mangrove plant-derived fungi and preparation method thereof | |
| CN107954839A (en) | A kind of antiinflammatory active compound peniroquesine A and its preparation method and application | |
| CN111960937B (en) | Mixed source terpenoid, preparation method thereof and application thereof in preparation of anti-breast cancer or dihydroorotate dehydrogenase inhibitor drugs | |
| CN110642863B (en) | 5,5,6 type PTM compound and preparation method and application thereof | |
| CN113773216A (en) | Long-chain fatty acid glycerol alcohol compound Rubracin A, preparation method and application thereof | |
| CN104450818B (en) | A kind of method and its application that pyrroles's acid compound is prepared using hickory chick | |
| CN110229131A (en) | The chromone derivatives and the preparation method and application thereof in ceriops tagal endogenetic fungus source | |
| CN110172410A (en) | A kind of aphthopyrans ketone compound in marine fungi source, preparation method and applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |